This represents a vast and growing population of patients for which there is a solid incentive to combine GLP-1RAs with cancer treatments, not by choice but out of necessity
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity (TA1152)
Ongoing monitoring should include regular review of weight loss progress, tolerability of side effects, and any changes in digestive symptoms
Footnotes Disclaimer/Publishers Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s)
For her, the hardest part was simply getting started
You might be wondering, Does what I eat while on GLP-1s actually matter? The short answer is yes, but not for the reasons you might think